MedWatch

French biotech company wants to challenge Novo and Lilly: "They are not unreachable"

Changed dynamics in the insulin market mean Novo Nordisk and Eli Lilly are not as  invincible as in the past, says a director from Adocia. The French biotech company aims to take on the giants - and also compete with Zealand Pharma in another segment of the diabetes market.

Foto: /Ritzau Scanpix/Asger Ladefoged

For a long time, Danish drug group Novo Nordisk and US-based Eli Lilly have had sort of a duopoly on the global mealtime insulin market. However, things might be about to change.

This is according to Savita Bernal, Director for Marketing and Corporate Communication and Business Development in French biotech company Adocia. With a new product at hand, the Lyon-based firm aims to challenge the market leaders.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier